KIT and cancer: As shown in Fig. 6B,E, the combination of NN2101‐DM1 and imatinib (for GIST) or chemotherapy (for SCLC) will overcome the limitations associated with downregulated expression of c‐Kit in cancer and exert potent therapeutic effects.